INTRODUCTION
============

The thiopurine drugs azathioprine (AZA) and 6-mercaptopurine (6-MP) have been used for many years for the treatment of numerous disorders, including UC, CD, acute lymphoblastic leukemia (ALL), and rheumatoid arthritis. In IBD (either UC or CD), thiopurines are used together with 5-aminosalicylic acid or the anti-tumor necrosis factor α antibodies infliximab and adalimumab to induce or maintain remission.[@B1][@B2]

Although thiopurine therapy has obvious clinical benefits in IBD, AZA and 6-MP occasionally induce severe adverse events such as leukopenia and alopecia. Thiopurine-induced severe leukopenia can result in infectious diseases with life-threatening consequences. Therefore, careful monitoring of white blood cell (WBC) count is required during treatment with these agents. Severe hair loss causes considerable stress to patients, and recovery may take more than 6 months following discontinuation of thiopurine therapy. These adverse events contribute to the interruption or discontinuation of thiopurine treatment. Therefore, genetic risk factors predictive of such thiopurine-induced effects have been studied in patients with IBD.[@B3] Certain polymorphisms of thiopurine methyltransferase (*TPMT*) are well-characterized genetic markers of risk of thiopurine-induced adverse events, and *TPMT* genotyping prior to initiation of thiopurine treatment is recommended by the U.S. Food and Drug Administration. However, it is believed that other factors affecting the risk of such adverse events are present in the Japanese population, since *TPMT* risk allele frequencies in this country are lower than those in Western countries, and the incidence of adverse reactions to thiopurines is high in Japan, even among carriers of wild-type *TPMT*.[@B3][@B4][@B5]

In 2014, Yang et al.[@B6] reported that a missense variant in exon 3 of the *NUDT15* gene (p.Arg139Cys or R139C; single nucleotide polymorphism \[SNP\] ID: rs116855232) strongly correlates with thiopurine-induced leukopenia among Korean patients with CD. The high specificity and sensitivity (89.4% and 93.2%, respectively) of *NUDT15* p.Arg139Cys recorded by these authors indicate that this variant, rather than *TPMT* polymorphisms, may be an effective genetic marker for predicting thiopurine-induced adverse events, at least in East Asian populations. To date, this strong association has been confirmed in numerous studies involving subjects with IBD or ALL.[@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18] In addition, a further investigation identified 4 *NUDT15* coding variants, including p.Arg139Cys, that influence both nucleotide diphosphatase activity and levels of thiopurine active metabolites, and found loss-of-function *NUDT15* variants to be associated with thiopurine intolerance.[@B13] Moreover, a more recent genome-wide association study conducted by Kim et al.[@B19] found an *FTO* coding variant and a proximal region of *RUNX1* to be associated with thiopurine-induced leukopenia among East Asian patients with IBD.

These findings suggest that the p.Arg139Cys coding variant of *NUDT15* may be a highly reliable marker of thiopurine cytotoxicity risk, especially in Asian populations. However, in patients lacking a risk-associated *TPMT* variant and *NUDT15* p.Arg139Cys, thiopurine cytotoxicity may be explained by the other abovementioned *NUDT15* coding sequence variations or *FTO* or *RUNX1* variants. Therefore, it is important to examine correlations between genes recently identified using genome-wide analysis and adverse clinical events.

Thus, in the present study, we investigated the associations between 3 coding variants in *NUDT15* and thiopurine-induced adverse events among Japanese subjects. Furthermore, we examined potential relationships between single sequence variations in *FTO* and *RUNX1* with such events in a Japanese population.

METHODS
=======

1. Patients
-----------

One hundred sixty Japanese patients with CD, UC, IBD unclassified, or intestinal Behçet disease having visited the Hyogo College of Medicine Hospital were included in this study. All patients, the characteristics of whom are shown in [Table 1](#T1){ref-type="table"}, were treated with AZA or 6-MP. This study was approved by the Ethical Review Board of Hyogo College of Medicine (approval number: Rin-hi-322), and written informed consent was obtained from all patients before their inclusion in this study.

2. Thiopurine Therapy for IBD and Adverse Events
------------------------------------------------

Initial AZA and 6-MP doses of 25 to 50 and 10 to 20 mg/day, respectively, were administered. Generally, signs of adverse events were checked 2 to 3 weeks after treatment initiation, and when none were detected, AZA and 6-MP doses were raised to 50 to 100 and 30 to 50 mg/day, respectively. Nausea is an adverse event commonly associated with thiopurine therapy. Mild nausea symptoms are usually transient, but severe nausea can lead to discontinuation of thiopurine treatment.[@B20] In this study, the group defined as having gastrointestinal (GI) intolerance to AZA included only those patients who discontinued AZA therapy because of GI symptoms such as severe nausea and epigastralgia. However, AZA-intolerant patients with associated GI symptoms who were successfully switched to 6-MP were not included in the GI intolerance group. We defined leukopenia as a WBC count \<3,000/µL, and severe hair loss as objective hair loss that might necessitate the wearing of a wig and requiring a few months for recovery.[@B7] Early or late leukopenia was defined as in previous studies (early leukopenia, within 8 weeks; late leukopenia, after 8 weeks).[@B6][@B7]

3. DNA Extraction
-----------------

Genomic DNA was extracted from peripheral blood using a Blood & Cell Culture DNA Midi Kit (Qiagen, Hilden, Germany) or a BioRobot EZ1 (Qiagen) at our college. Of the 160 blood samples, 39 collected between June and November 2016 were sent to the LSI Medience Corporation (Tokyo, Japan) for DNA extraction and analysis.

4. SNP Genotyping
-----------------

Genotyping of *NUDT15* p.Arg139Cys (rs116855232), *FTO* p.Ala134Thr (rs79206939), and a proximal region of *RUNX1* (rs2834826) was performed using TaqMan SNP Genotyping Assays (assay IDs: C_154823200_10, C_102162425_10, and C_3266345_10, respectively) with TaqMan Genotyping Master Mix (Thermo Fisher Scientific, Waltham, MA, USA). Real-time PCR and allelic discrimination analysis were carried out using an ABI 7500 system (Applied Biosystems, Foster City, CA, USA). As PCR using probes for *NUDT15* p.Arg139Cys is not effective for samples from individuals carrying *NUDT15* p.Arg139His (rs147390019), genotyping of the latter was attempted by Sanger sequencing when the TaqMan SNP Assay for the former failed. The primer sequences used for Sanger sequencing of *NUDT15* exon 3 were as follows: forward, AAGCAAATGCAAAGCATCAC; and reverse, GGCTGAAAGAGTGGGGGATA.[@B13] The primers used to detect both *NUDT15* p.Val18_Val19insGlyVal (rs554405994) and p.Val18Ile (rs186364861) in exon 1 using Sanger sequencing were as follows: forward, CAAAGCACAACTGTAAGCGACT; and reverse, GAAAGACCCAGCTAGCAAAGAC.[@B13] The PCR products were purified using an ExoSAP-IT PCR Product Cleanup Kit (Affymetrix, Santa Clara, CA, USA), and sequencing was performed using a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). The sequencing products were purified with a BigDye XTerminator™ Purification Kit and analyzed on a 3130xl or 3500xl genetic analyzer (Applied Biosystems).

5. Statistical Analysis
-----------------------

Categorical variables were compared using the chi-square test, or Fisher test when the expected value of any cell was less than 5. A Mann-Whitney or Kruskal-Wallis test was used to compare the difference in thiopurine dose or interval between each genotype. Statistical analysis was conducted using GraphPad Prism version 6.07 (GraphPad Software, La Jolla, CA, USA) and *P*-values \<0.05 were considered statistically significant.

RESULTS
=======

1. Patient Baseline Characteristics and Genotype Frequencies for Each Variant
-----------------------------------------------------------------------------

We recruited 160 patients with CD, UC, IBD unclassified, or intestinal Behçet disease in this study, the characteristics of whom are summarized in [Table 1](#T1){ref-type="table"}. The mean age of patients with leukopenia was significantly higher than that of those without leukopenia (*P*=0.0069). Although 6-MP-treated patients were more predisposed to leukopenia than AZA-treated patients, this is likely because physicians preferentially administer 6-MP, which exists as a powdered formulation suitable for small dose reductions, to thiopurine-treated patients whose WBC count declines. No significant differences were observed with respect to sex, body weight, disease type, use of co-medications such as 5-aminosalicylic acid, prednisolone, and anti-tumor necrosis factor α agents, initial thiopurine dose, or follow-up period.

Genotype frequencies of the 6 variants analyzed are shown in [Table 2](#T2){ref-type="table"}. Of the 160 subjects, 11 (6.9%), 2 (1.2%), and 9 (5.6%) were heterozygous for *NUDT15* p.Val18_Val19insGly-Val, *NUDT15* p.Val18Ile, and *FTO* p.Ala134Thr, respectively. None were homozygous for these variants. Wild-type, heterozygous, and homozygous variant *NUDT15* p.Arg139Cys genotypes were carried by 117 (73.1%), 35 (21.9%), and 8 (5.0%) patients, respectively. For the rs2834826 noncoding sequence variation in *RUNX1*, 60 wild-type (37.5%), 80 heterozygous (50.0%), and 20 homozygous variant (12.5%) individuals were identified. The *NUDT15* p.Arg139His variant was not detected in our study sample.

2. Three *NUDT15* Coding Variants and GI Intolerance to AZA
-----------------------------------------------------------

Of the 160 patients, 10 AZA- and 1 6-MP-treated patient experienced intolerable epigastralgia or nausea after initiation of therapy, and treatment was therefore discontinued. First, we investigated the correlation between GI intolerance to AZA and the coding variants of *NUDT15*. Nitroimidazole, which derives from AZA and causes nausea, is absent from 6-MP.[@B21] Treatment with 6-MP may thus help to prevent or diminish nausea.[@B22] Therefore, only AZA-treated patients were included in this analysis ([Table 3](#T3){ref-type="table"}).

The 4 nucleotide sequence variations leading to changes in the amino acid sequence of the *NUDT15* protein are located in exon 1 (rs554405994 \[p.Val18_Val19insGlyVal\] and rs186364861 \[p.Val18Ile\]) and exon 3 (rs116855232 \[p.Arg139Cys\] and rs147390019 \[p.Arg139His\]).[@B13] The 3 *NUDT15* coding variants identified in our study group (p.Val18_Val19insGlyVal, p.Val18Ile, and p.Arg139Cys) were not significantly associated with GI intolerance to AZA ([Table 3](#T3){ref-type="table"}). However, comparing *NUDT15* p.Arg139Cys genotypes with respect to the interval between initiation and discontinuation of AZA therapy revealed that patients carrying the C/T or T/T genotype discontinued AZA significantly earlier than those with the wild-type C/C genotype ([Fig. 1](#F1){ref-type="fig"}). These data suggest that although GI intolerance to AZA occurred regardless of *NUDT15* genotype, p.Arg139Cys risk allele carriers discontinued AZA earlier than wild-type carriers owing to differing symptom severity.

3. Correlation between *NUDT15* Variants and Leukopenia and Severe Hair Loss
----------------------------------------------------------------------------

The *NUDT15* p.Arg139Cys variant is in current use as a reliable marker of risk of thiopurine-induced leukopenia and severe hair loss. However, it remains unclear whether other coding variants also cause these adverse events in patients with IBD. Therefore, we next analyzed the correlation between 3 *NUDT15* coding variants and these events. The 11 subjects who, due to GI intolerance, discontinued AZA ([Table 3](#T3){ref-type="table"}) or 6-MP therapy 1 to 9 weeks after its initiation were excluded from this analysis, since this time period was insufficient to evaluate leukopenia or severe hair loss. One hundred forty-nine subjects were therefore assessed, and the results are presented in [Table 4](#T4){ref-type="table"}. The frequencies of p.Val18_Val19insGlyVal, p.Val18Ile, and p.Arg139Cys alleles were similar to those shown in [Table 3](#T3){ref-type="table"}. The coding variants in exon 1 of *NUDT15* (p.Val18_Val19insGlyVal and p.Val18Ile) were not associated with leukopenia or severe hair loss. In contrast, strong associations with that in exon 3 (p.Arg139Cys) were evident. The *P*-value for the relationship between p.Val18_Val19insGlyVal genotype and leukopenia (no leukopenia versus combined early and late leukopenia) was 0.0512. However, this variant is in high linkage disequilibrium with p.Arg139Cys;[@B13] therefore, the effect of p.Val18_Val19insGlyVal alone may not be strong.

We identified 2 subjects heterozygous for the p.Val18Ile variant, both of whom exhibited late leukopenia. However, this relationship was not statistically significant (*P*=0.1029) owing to the relatively small sample size. These 2 patients developed leukopenia approximately 3 years after initiation of AZA treatment, and quickly recovered after interruption of this therapy, without granulocyte-colony stimulating factor administration.

4. Analysis of *NUDT15* p.Arg139Cys Genotype and Interval to Leukopenia and Thiopurine Dose
-------------------------------------------------------------------------------------------

Further analysis of p.Arg139Cys genotypes was performed, the results of which are shown in [Fig. 2](#F2){ref-type="fig"}. The mean interval from initiation of thiopurine therapy to leukopenia among subjects carrying the C/C, C/T, and T/T genotype was 19.81, 13.67, and 1.01 months, respectively (*P*=0.0009) ([Fig. 2A](#F2){ref-type="fig"}). None of the patients with the T/T genotype were able to continue thiopurine therapy for more than 9 weeks due to GI intolerance, leukopenia, or severe hair loss. To compare the average thiopurine dose administered between each genotype, we considered only subjects having continued thiopurine therapy for more than 1 year. Carriers of the C/T genotype tended to require frequent reductions in thiopurine dose during the first year of therapy due to leukopenia. As a result, average thiopurine doses given to patients with the C/T genotype were significantly lower than those administered to C/C genotype carriers (0.77 and 1.01 mg/kg/day, respectively; *P*=0.0296) ([Fig. 2B](#F2){ref-type="fig"}).

5. *FTO* p.Ala134Thr and the rs2834826 Noncoding Variant in the Proximal Region of *RUNX1* Are Not Associated with Leukopenia or Severe Hair Loss among Japanese Patients with IBD
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Many *FTO* and *RUNX1* loci have been associated with thiopurine-induced leukopenia in the East Asian population.[@B19] In particular, a non-synonymous coding sequence variation in *FTO* (p.Ala134Thr, rs79206939) has been shown to reduce *FTO* activity. Consistent with these results, *FTO*^−/−^ and *FTO*^+/−^ mice exhibit increased sensitivity to thiopurine.[@B19] Therefore, we investigated the association of the *FTO* p.Ala134Thr variation and a noncoding variant in the proximal region of *RUNX1* (rs2834826) with thiopurine-induced leukopenia and severe hair loss among Japanese patients with IBD.

Nine subjects were heterozygous for the A risk allele of *FTO* p.Ala134Thr. Of these, 4 developed leukopenia, but this association was not statistically significant (*P*=0.7404). Moreover, none of the 9 patients exhibited severe hair loss. *RUNX1* rs2834826 was not associated with leukopenia or severe hair loss (*P*=0.4869 and *P*=0.5023, respectively) ([Table 5](#T5){ref-type="table"}).

DISCUSSION
==========

AZA and 6-MP have been widely used as immunomodulators and chemotherapeutic agents for the treatment of various diseases. At our hospital, more than 100 patients with IBD commence thiopurine therapy each year, and this number is increasing due to the growing incidence of IBD in Japan. Every year, several patients present with early leukopenia or severe hair loss after initiating thiopurine treatment. To date, for such patients carrying the wild-type *TPMT* genotype, the cause of these adverse events could not be determined.

Discovery of the association between *NUDT15* p.Arg139Cys and thiopurine-induced leukopenia among Korean CD patients may enable unprecedented progress in the management of adverse thiopurine effects in the East Asian population.[@B6] Importantly, many investigators have been able to replicate these results in studies of thiopurine-treated patients with IBD or ALL.[@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18] In the current study, we successfully established a significant association between *NUDT15* p.Arg139Cys and thiopurine-induced leukopenia and severe hair loss.

We obtained evidence that this variant correlates with the time interval between AZA initiation and GI intolerance to this drug ([Fig. 1](#F1){ref-type="fig"}). The abnormal accumulation of thiopurine metabolites in patients carrying p.Arg139Cys may accelerate development of strong nausea. However, our results in this respect may be limited by certain arbitrary aspects of the analysis, given the subjectivity of nausea and that the decision to discontinue thiopurine therapy is dependent on physicians and patients.

As evidence of the role of *NUDT15* in thiopurine treatment accumulates, the demand for *NUDT15* genotyping prior to such therapy is increasing in Japan. Although these replicable results should be translated into clinical practice, further evaluation of *NUDT15* variants is necessary before clinical application. Consequently, we investigated three coding sequence variations in *NUDT15* identified by Moriyama et al.[@B13] No association between the p.Val18_Val19insGlyVal and p.Val18Ile variants and leukopenia or severe hair loss was evident in our study. However, it should be noted that these adverse events did occur more frequently among subjects heterozygous for these coding variants ([Table 4](#T4){ref-type="table"}); therefore, it is likely that they are significantly more common among homozygous risk allele carriers, as observed in relation to the p.Arg139Cys mutation. The strong linkage disequilibrium between p.Val18_Val19insGlyVal and p.Arg139Cys should be taken into account however.[@B13] These coding variants result in 74.4% to 100% loss of NUDT15 enzymatic activity.[@B13] Therefore, carriers of the exon 1 variation may need to be followed-up carefully to monitor for signs of leukopenia. Future studies are expected to shed light on the importance of p.Val18_Val19insGlyVal and p.Val18Ile as predictive markers of thiopurine-induced adverse events.

In our study sample, 8 subjects homozygous for the T allele of *NUDT15* p.Arg139Cys were identified. One of these individuals discontinued AZA therapy within 7 days following its initiation due to intolerable GI symptoms ([Table 3](#T3){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}). Six of the 8 subjects were able to continue AZA treatment for more than 2 weeks, but discontinued it because of early or late leukopenia, the latter being detected at 9 weeks ([Table 4](#T4){ref-type="table"}). All of the homozygous T/T subjects with leukopenia exhibited grade 4 leukopenia (defined as a WBC \<1,000 cells/µL) and required both granulocyte-colony stimulating factor and antibiotics. Only 1 patient carrying this genotype did not develop leukopenia. However, all 7 patients who continued thiopurine therapy for more than 2 weeks experienced severe hair loss. Therefore, administration of thiopurines to patients with the *NUDT15* p.Arg139Cys T/T genotype caused drastic adverse events. We currently do not use thiopurine therapy for patients with IBD and this genotype because it is contraindicated. It remains unclear whether an extremely low dose of 6-MP would be tolerable or clinically efficacious for Japanese carriers of this genotype suffering IBD.

The physiological function of NUDT15 is considered to be the hydrolysis of 8-oxo-dGTP generated from reactive oxygen species.[@B23] Recent studies indicate that NUDT15 preferentially inactivates thiopurine metabolites over 8-oxo-dGTP,[@B24] converting those such as TGTP and TdGTP to TGMP and TdGMP, respectively.[@B13] NUDT15 is a negative regulator that decreases levels of bioactive thiopurine metabolites, the cytotoxicity of which is therefore increased by loss-of-function variants. Our data obtained from analyzing adverse events among thiopurine-treated patients indicate that the NUDT15 Arg139Cys site may be more critical to thiopurine metabolism than those loci affected by the other coding variants examined. The precise molecular mechanisms by which the p.Arg139Cys mutation leads to thiopurine-induced cell death remain unclear.

The site of the Arg139Cys mutation is reported to be within the TGTP-binding pocket of the NUDT15 protein. Substitution of arginine with cysteine at this position may affect the enzyme\'s structure, and thereby, reduce cellular TGTP hydrolysis.[@B24] One study has shown that NUDT15 proteins harboring the Arg139Cys mutation demonstrate enzyme activity comparable to that of the wild-type form, but are degraded rapidly in cells.[@B25] Therefore, NUDT15 protein level may be implicated in the cytotoxicity of and sensitivity to thiopurines. The development of biochemical tests of NUDT15 enzymatic activity would be beneficial.

Sequence variations in the genes *FTO* and *RUNX1* identified using a genome-wide association study are also promising candidates as predictive markers of thiopurine cytotoxicity.[@B19] However, we could not verify the association between thiopurine-induced adverse events and *FTO* p.Ala134Thr and a noncoding variant in the proximal region of *RUNX1* among Japanese patients with IBD. This may be due to differences between Korean and Japanese patients with this condition in terms of the thiopurine doses administered. We usually initiate AZA and 6-MP treatment at relatively low doses (25 and 10--20 mg/day, respectively), and sometimes gradually increase the dose while paying attention to the development of adverse events such as GI symptoms and leukopenia. For Japanese patients with IBD, even low doses of thiopurines are clinically effective and result in therapeutic concentrations of the thiopurine metabolite 6-thioguanine nucleotide;[@B26][@B27] therefore, the AZA maintenance dose of 25 to 100 mg/day (equivalent to 0.5--2.0 mg/kg/day for a patient weighing 50 kg) is commonly used, as shown in [Fig. 2B](#F2){ref-type="fig"}. We did not identify any homozygous *FTO* p.Ala134Thr risk allele carriers in this study, who are expected to exhibit more prominent effects of thiopurine exposure. As our sample size was not large enough, further analysis will be required to elucidate the association between these genes and thiopurine-induced adverse events in the Japanese population.

In summary, we verified the strong association between *NUDT15* p.Arg139Cys and thiopurine-induced early and late leukopenia and severe hair loss among Japanese patients with IBD. However, *NUDT15* p.Val18_Val19insGlyVal, *NUDT15* p.Val18Ile, *FTO* p.Ala134Thr, and a noncoding variant in the proximal region of *RUNX1* (rs2834826) were not associated with these adverse events. Thus, *NUDT15* p.Arg139Cys genotyping should currently be prioritized for the prediction of thiopurine-induced adverse events among Japanese patients with IBD, and its application in precision medicine should be considered in the future.
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###### Baseline Characteristics of Patients

![](ir-15-328-i001)

  Variable                                      Total                 No leukopenia         Leukopenia            *P*-value^a^
  --------------------------------------------- --------------------- --------------------- --------------------- --------------
  Sex (male/female)                             96/64                 60/41 (59.4/40.6)     36/23 (61.0/39.0)     0.8686
  Age (yr)                                      40.3 (18--74)         38.3 (18--74)         43.6 (20--74)         0.0069
  Body weight (kg)                              54.6 (37--90)         53.7 (31--80)         54.4 (38--77)         0.6358
  Diagnosis                                                                                                       0.2706
   CD                                           86                    57 (66.3)             29 (33.7)             
   UC                                           72                    44 (61.1)             28 (38.9)             
   IBDu                                         1                     0                     1 (100.0)             
   Intestinal Behçet                            1                     0                     1 (100.0)             
  5-ASA                                         0151                  98 (64.9)             53 (35.1)             0.0767
  Prednisolone                                  94                    59 (62.8)             35 (37.2)             0.9106
  Anti-TNF-α agent (infliximab or adalimumab)   89                    62 (69.7)             27 (30.3)             0.0697
  AZA/6-MP                                      123/37                84/17 (83.2/16.8)     39/20 (66.1/33.9)     0.0135
  Initial AZA dose (mg/kg/day)                  0.759±0.247           0.757±0.229           0.764±0.287           0.5760
  Initial 6-MP dose (mg/kg/day)                 0.316±0.167           0.282±0.098           0.331±0.196           0.9680
  Follow-up period of thiopurine therapy (mo)   43.6 (0.25--132.00)   42.1 (0.25--132.00)   46.0 (0.50--126.00)   0.9965

Values are presented as number (%), mean (range), or mean±SD.

^a^No leukopenia vs. leukopenia.

IBDu, IBD unclassified; 5-ASA, 5-aminosalicylic acid; TNF-α, tumor necrosis factor α; AZA, azathioprine; 6-MP, 6-mercaptopurine.

###### Genotype Frequencies in Variants of *NUDT15*, *FTO*, and *RUNX1*

![](ir-15-328-i002)

  Genotype                          Total (n=160)   CD (n=86)   UC (n=72)   IBDu (n=1)   Intestinal Behçet (n=1)
  --------------------------------- --------------- ----------- ----------- ------------ -------------------------
  *NUDT15* p.Val18_Val19insGlyVal                                                        
   -/-                              149 (93.1)      80 (53.7)   67 (45.0)   1 (0.7)      1 (0.7)
   -/GGAGTC                         11 (6.9)        6 (54.5)    5 (45.5)    0            0
  *NUDT15* p.Val18Ile                                                                    
   G/G                              158 (98.8)      85 (53.8)   71 (44.9)   1 (0.6)      1 (0.6)
   G/A                              2 (1.2)         1 (50.0)    1 (50.0)    0            0
  *NUDT15* p.Arg139Cys                                                                   
   C/C                              117 (73.1)      68 (58.1)   49 (41.9)   0            0
   C/T                              35 (21.9)       15 (42.9)   18 (51.4)   1 (2.9)      1 (2.9)
   T/T                              8 (5.0)         3 (37.5)    5 (62.5)    0            0
  *NUDT15* p.Arg139His                                                                   
   G/G                              160 (100.0)     86 (53.8)   72 (45.0)   1 (0.6)      1 (0.6)
   G/A                              0               0           0           0            0
  *FTO* p.Ala134Thr                                                                      
   G/G                              151 (94.3)      82 (54.3)   68 (45.0)   1 (0.7)      0
   G/A                              9 (5.6)         4 (44.4)    4 (44.4)    0            1 (11.1)
  *RUNX1*intergenic (rs2834826)                                                          
   C/C                              60 (37.5)       31 (51.7)   29 (48.3)   0            0
   C/T                              80 (50.0)       45 (56.3)   33 (41.3)   1 (1.3)      1 (1.3)
   T/T                              20 (12.5)       10 (50.0)   10 (50.0)   0            0

Values are presented as number (%).

IBDu, IBD unclassified.

###### No Correlation between *NUDT15* Genotypes and the Incidence of GI Intolerance to Azathioprine
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  Gene                *NUDT15*                                                                                        
  ------------------- ------------ ---------- -------- ------------ --------- ---- ----------- ----------- ---------- --------
  No. of patients     116 (94.3)   7 (5.7)             121 (98.4)   2 (1.6)        93 (75.6)   22 (17.9)   8 (6.5)    
  Male/female         66/50        6/1                 71/50        1/1            54/39       13/9        5/3        
  No GI intolerance   107 (94.7)   6 (5.3)             111 (98.2)   2 (1.8)        86 (76.1)   20 (17.7)   7 (6.2)    
  GI intolerance      9 (90.0)     1 (10.0)   0.4562   10 (100.0)   0         \-   7 (70.0)    2 (20.0)    1 (10.0)   0.8706

Values are presented as number (%).

GI, gastrointestinal; SNP, single nucleotide polymorphism.

###### Associations between *NUDT15* Genotype and Leukopenia and Severe Hair Loss

![](ir-15-328-i004)

  Gene                  NUDT15                                                                                                
  --------------------- ------------ ---------- -------- ------------ --------- -------- ------------ ----------- ----------- ----------
  No. of patients       139 (93.3)   10 (6.7)            147 (98.7)   2 (1.3)            109 (73.2)   33 (22.1)   7 (4.7)     
  Male/female           82/57        8/2                 89/58        1/1                65/44        21/12       4/3         
  No leukopenia         87 (96.7)    3 (3.3)             90 (100.0)   0                  80 (88.8)    9 (10.0)    1 (1.1)     
  Leukopenia            52 (88.1)    7 (11.9)   0.0512   57 (96.6)    2 (3.4)   0.1552   29 (49.1)    24 (40.7)   6 (10.2)    \<0.0001
   Early leukopenia     14 (87.5)    2 (12.5)   0.1629   16 (100.0)   0         \-       3 (18.7)     8 (50.0)    5 (31.3)    \<0.0001
   Late leukopenia      38 (88.4)    5 (11.6)   0.1113   41 (95.3)    2 (4.7)   0.1029   26 (60.5)    16 (37.2)   1 (2.3)     0.0006
  No severe hair loss   132 (93.0)   10 (7.0)            140 (98.6)   2 (1.4)            109 (76.8)   33 (23.2)   0           
  Severe hair loss      7 (100.0)    0          \-       7 (100.0)    0         \-       0            0           7 (100.0)   \<0.0001

Values are presented as number (%).

SNP, single nucleotide polymorphism.

###### No association of *FTO* and *RUNX1* with Leukopenia and Severe Hair Loss in a Japanese Population

![](ir-15-328-i005)

  Gene                  *FTO*        *RUNX1*                                                
  --------------------- ------------ --------- -------- ----------- ----------- ----------- --------
  No. of patients       140 (94.0)   9 (6.0)            56 (37.6)   73 (49.0)   20 (13.4)   
  Male/female           84/56        6/3                35/21       46/27       9/11        
  No leukopenia         85 (94.4)    5 (5.6)            33 (36.7)   47 (52.2)   10 (11.1)   
  Leukopenia            55 (93.2)    4 (6.8)   0.7404   23 (39.0)   26 (44.1)   10 (16.9)   0.4869
   Early leukopenia     15 (93.7)    1 (6.3)   \-       5 (31.2)    8 (50.0)    3 (18.8)    0.6803
   Late leukopenia      40 (93.0)    3 (7.0)   0.7130   18 (41.9)   18 (41.9)   7 (16.3)    0.4839
  No severe hair loss   133 (93.7)   9 (6.3)            52 (36.6)   71 (50.0)   19 (13.4)   
  Severe hair loss      7 (100.0)    0                  4 (57.1)    2 (28.6)    1 (14.3)    0.5023

Values are presented as number (%).

SNP, single nucleotide polymorphism.

[^1]: ^\*^These authors contributed equally to this study.
